Sema4, an AI- and machine learning-driven patient-centered genomic and clinical data intelligence company, and CM Life Sciences today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, CM Life Sciences will be renamed and its common stock will list on the Nasdaq under a name and a ticker symbol to be announced.
The combination is expected to provide up to $793 million in cash proceeds to shareholders and Sema4.
Financing includes a fully committed PIPE of $350 million from growth and life science investors including Casdin Capital, Corvex Management, Fidelity Management & Research Company, Counterpoint Global (Morgan Stanley), Perceptive Advisors, SB Management, a subsidiary of SoftBank Group Corp, funds and accounts advised by T. Rowe Price Associates Inc and Viking Global Investors, and existing investors including fund and accounts managed by Blackrock and Deerfield Management. Read more.
